Mark Levine - Immunovant Chief Secretary
| IMVT Stock | USD 19.69 0.81 4.29% |
Executive
Mark Levine is Chief Secretary of Immunovant
| Age | 51 |
| Address | 320 West 37th Street, New York, NY, United States, 10018 |
| Phone | 917 580 3099 |
| Web | https://immunovant.com |
Immunovant Management Efficiency
The company has return on total asset (ROA) of (0.4473) % which means that it has lost $0.4473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7417) %, meaning that it created substantial loss on money invested by shareholders. Immunovant's management efficiency ratios could be used to measure how well Immunovant manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.37 in 2025. Return On Capital Employed is likely to gain to -0.5 in 2025. Total Current Liabilities is likely to gain to about 58.7 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 386.8 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Huw Nash | Stoke Therapeutics | 57 | |
| Delphine Imbert | Pliant Therapeutics | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| James JD | Legend Biotech Corp | N/A | |
| Matthew JD | Protagonist Therapeutics | 54 | |
| Christina MBA | Blueprint Medicines Corp | 49 | |
| John CPA | Arcutis Biotherapeutics | 71 | |
| Thomas Ross | Akero Therapeutics | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Christopher Keenan | Pliant Therapeutics | N/A | |
| Lily Cheung | Pliant Therapeutics | 52 | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| Bethany Dudek | Arcutis Biotherapeutics | N/A | |
| Kent Taylor | Arcutis Biotherapeutics | N/A | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| BA Esq | Arbutus Biopharma Corp | 57 | |
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| Mike JD | Pliant Therapeutics | 52 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.45 |
Immunovant Leadership Team
Elected by the shareholders, the Immunovant's board of directors comprises two types of representatives: Immunovant inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunovant. The board's role is to monitor Immunovant's management team and ensure that shareholders' interests are well served. Immunovant's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunovant's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jay Stout, Chief Officer | ||
| Mark Levine, Chief Secretary | ||
| Lauren MBA, Vice Marketing | ||
| JD Esq, Chief Secretary | ||
| Eva MBA, Chief Officer | ||
| Julie Kirschling, Senior Management | ||
| Christine Blodgett, Senior Resources | ||
| MBA MD, Ex Board | ||
| MD MBA, Executive Board | ||
| Mark JD, Chief Secretary | ||
| Julia Butchko, Chief Officer | ||
| Andy Deig, Senior Finance | ||
| Christopher Tuyl, Chief Secretary | ||
| Melanie BSN, Chief Officer | ||
| Chau MBA, Vice Relations |
Immunovant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunovant a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 2.83 B | ||||
| Shares Outstanding | 169.86 M | ||||
| Shares Owned By Insiders | 58.07 % | ||||
| Shares Owned By Institutions | 47.58 % | ||||
| Number Of Shares Shorted | 14.79 M | ||||
| Price To Book | 9.09 X | ||||
| EBITDA | (269.98 M) | ||||
| Net Income | (259.34 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.